alexander perl, md, on flt3 inhibitors in development and importance of hitting the flt3 target
Published 8 years ago • 43 plays • Length 1:18
Download video MP4
Download video MP3
Similar videos
-
1:25
alexander perl, md, on importance of flt3 and provides his perspective on inhibitor differences
-
0:58
alexander perl, md, discusses the importance of sustained inhibition when selecting a flt3 inhibitor
-
1:14
alexander perl, md, discusses the potential impact of potency when selecting a flt3 inhibitor
-
9:39
alexander perl, md: the new flt3 inhibitor gilteritinib is “well-tolerated” in aml
-
1:40
alexander perl, md, discusses treatment options for patients with flt3-itd positive aml
-
1:17
alexander perl, md, on the role of immunotherapy in treating hematological malignancies
-
1:50
mark levis, md, on why the flt3 target is important in aml
-
0:54
alexander perl, md, discusses abstract 7008 results and crenolanib potential activity
-
2:10
alexander perl, md, on prognosis, diagnosis and treatment strategies for aml
-
0:53
alexander perl, md, discusses the quantum first study and potential implications
-
0:41
alexander perl, md, on the toxicity in the phase 3 study evaluating cpx-351 (vyxeos)
-
0:59
alexander perl, md, discusses how molecular testing can facilitate decision making in aml patients
-
1:25
dr. perl on the outlook of flt3 inhibitors for aml
-
1:59
alexander perl, md, discusses treatment options for aml patients
-
5:49
emerging flt3 inhibitors in aml
-
1:08
mark levis, md discusses importance of hitting the flt3 target in aml patients with this mutation
-
1:22
alexander perl, md, on aml trial results presented at this year’s ash meeting
-
1:23
alexander perl, md discusses cpx-351 (vyxeos) mechanism of action and why it is a promising agent
-
1:32
novel treatment combinations for flt3-mutated aml
Clip.africa.com - Privacy-policy